These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9698932)

  • 1. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin.
    Teixeira MM; Miotla JM; Cooper N; Gristwood RW; Hellewell PG
    Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():193-6. PubMed ID: 9698932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
    Cooper N; Teixeira MM; Warneck J; Miotla JM; Wills RE; Macari DM; Gristwood RW; Hellewell PG
    Br J Pharmacol; 1999 Apr; 126(8):1863-71. PubMed ID: 10372831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
    Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
    Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
    Souness JE; Villamil ME; Scott LC; Tomkinson A; Giembycz MA; Raeburn D
    Br J Pharmacol; 1994 Apr; 111(4):1081-8. PubMed ID: 8032594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
    Silva PM; Alves AC; Serra MF; Pires AL; Silva JP; Barreto EO; Cordeiro RS; Jose PJ; Teixeira MM; Lagente V; Martins MA
    Br J Pharmacol; 2001 Sep; 134(2):283-94. PubMed ID: 11564646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
    Hatzelmann A; Tenor H; Schudt C
    Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.
    Souness JE; Scott LC
    Biochem J; 1993 Apr; 291 ( Pt 2)(Pt 2):389-95. PubMed ID: 8387267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.
    Tenor H; Hatzelmann A; Church MK; Schudt C; Shute JK
    Br J Pharmacol; 1996 Aug; 118(7):1727-35. PubMed ID: 8842438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aryl sulfonamides as selective PDE4 inhibitors.
    Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs.
    Dent G; Poppe H; Egerland J; Marx D; Szelenyi I; Branscheid D; Magnussen H; Rabe KF
    Pulm Pharmacol Ther; 1998 Feb; 11(1):13-21. PubMed ID: 9802959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
    Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
    Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.
    Teixeira MM; Rossi AG; Giembycz MA; Hellewell PG
    Br J Pharmacol; 1996 Aug; 118(8):2099-106. PubMed ID: 8864548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
    Au BT; Teixeira MM; Collins PD; Williams TJ
    Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.